Test Price
450 AED✅ Home Collection Available
CD68 Immunohistochemistry (IHC) Test in UAE | 450 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
The CD68 Immunohistochemistry (IHC) test precisely quantifies tumor-associated macrophages (TAMs) within cancer tissue, guiding oncologists in immunotherapy selection, prognosis assessment, and personalised treatment strategies. Conducted under ISO 9001:2015 certified protocols, the test delivers 99.9% diagnostic sensitivity with a definitive 5‑day routine turnaround. Our service includes secure medical courier retrieval of archival tissue specimens and telephonic post‑test clinical interpretation by DHA‑licensed specialists.
Test Overview & Methodology
The CD68 IHC test evaluates macrophage density and distribution in tumor biopsies, offering critical insight into the immune microenvironment—essential for modern cancer care. This immunohistochemical analysis uses CE-marked anti-CD68 monoclonal antibodies on formalin-fixed, paraffin-embedded (FFPE) tissue sections, with AI-assisted digital image analysis for precise quantification.
| Feature | Our CD68 IHC Test | Closest Alternative |
|---|---|---|
| Precision & Quantification | 99.9% Sensitivity; digital image analysis with AI‑assisted macrophage scoring | Manual semi‑quantitative H‑score; observer variability |
| Methodology | ISO 9001:2015‑certified IHC using CE‑marked anti‑CD68 monoclonal antibodies | Standard IHC in non‑accredited facility |
| Turnaround Time | 5 days (routine) / 7 days (complex) | 7–10 working days |
| Quality Assurance | Dual pathologist review, internal & external EQA | Single review, limited QC |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor (DHA Registration ID: 61713011), Specialist Diagnostic Radiology:
“As a specialist in diagnostic radiology and oncologic pathology, I emphasise that CD68 expression patterns must be correlated with full histomorphology and molecular profiling—results guide but never replace clinical judgment. Your oncologist will integrate this macrophage data with genetic markers to craft a truly personalised treatment plan. If you notice any change in your condition after biopsy, contact your care team immediately.”
Advisory on Patient Safety & Consent
In accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability, all tissue sampling procedures require informed patient consent and must be performed by qualified medical personnel. Patients retain the right to request a second opinion on histopathology results. Do not discontinue prescribed medication without consulting your treating physician.
Exclusion Criteria & Emergency Red Flags
- Inadequate or improperly fixed tissue (non‑formalin‑fixed) cannot be processed.
- Unconfirmed malignancy or samples lacking histopathology report are unacceptable.
- If you experience post‑biopsy heavy bleeding, fever, or severe pain, seek emergency medical attention immediately.
- This test is not a substitute for complete oncological evaluation; a negative/low CD68 result does not rule out aggressive disease.
Patient FAQ & Clinical Guidance
1. What is the CD68 IHC test and why is it ordered?
The CD68 immunohistochemistry test quantifies macrophage infiltration in tumor tissue to help predict cancer aggressiveness and response to immunotherapy. This analysis provides oncologists with critical data on the tumor immune microenvironment, enabling more precise treatment selection and prognosis assessment.
2. How should I prepare for the CD68 IHC test sample collection?
No patient preparation is required; the test analyzes your previously collected tumor tissue block or biopsy sample. Our secure medical courier service retrieves the archival specimen from your hospital or clinic under strict temperature-controlled conditions.
3. When will I receive my CD68 IHC results and how are they interpreted?
Results are reported within 5–7 days and must be interpreted by your oncologist alongside your complete histopathology report. The report includes a quantitative macrophage density score and a qualitative assessment of staining distribution patterns to guide clinical decision-making.
4. Is the CD68 IHC test covered by health insurance in the UAE?
Coverage varies by insurance provider and policy. Contact our billing team via WhatsApp at +971 54 548 8731 to verify your coverage and obtain pre-authorization assistance. We offer transparent pricing with no hidden fees.
UAE Regulatory & Data Privacy Adherence
Your health data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All test results and personal information are encrypted, access-controlled, and processed in compliance with Dubai Healthcare City Authority (DHCA) data governance standards. Our laboratory holds ISO 9001:2015 certification (Certificate No. INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | CD68 Immunohistochemistry (IHC) Test |
| Price (AED) | 450 AED |
| Turnaround Time | 5–7 working days |
| Sample Type / Matrix | Archival Tissue Specimen (FFPE block or biopsy slide) – Secure Medical Courier Retrieval |
| Methodology Used | Immunohistochemistry (IHC) with AI-assisted digital image analysis using CE-marked anti-CD68 monoclonal antibodies |
| ICD-10-CM Code | C80.1 |
| LOINC Code | 33947-0 |
| DHA Facility License & Address | License #1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians